Comparative Pharmacology
Head-to-head clinical analysis: OSMOLEX ER versus SCOPOLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSMOLEX ER versus SCOPOLAMINE.
OSMOLEX ER vs SCOPOLAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic receptors in the striatum, helping to restore the balance between acetylcholine and dopamine in the basal ganglia, thereby reducing extrapyramidal symptoms.
Scopolamine is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the action of acetylcholine at these receptors in the central nervous system and periphery.
Initial: 1 mg orally once daily; titrate by 1 mg every 3-5 days based on response and tolerability. Maximum: 8 mg once daily. Administer at bedtime.
1.5 mg transdermal patch applied to postauricular skin every 72 hours; for prevention of motion sickness, apply 4-5 hours before exposure. Alternatively, 0.3-0.65 mg intramuscularly or intravenously every 6-8 hours as needed; or 0.4-0.8 mg subcutaneously. Oral dose: 0.4-0.8 mg every 6-8 hours as needed.
None Documented
None Documented
Clinical Note
moderateScopolamine + Venlafaxine
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Venlafaxine."
Clinical Note
moderateScopolamine + Nefazodone
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Nefazodone."
Clinical Note
moderateScopolamine + Stiripentol
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Stiripentol."
Clinical Note
moderateScopolamine + Fesoterodine
Terminal elimination half-life is 5-8 hours in healthy adults; prolonged in renal impairment (up to 16 hours in severe impairment).
Terminal elimination half-life is approximately 2–4 hours in adults; in elderly or hepatic impairment, half-life may be prolonged.
Primarily renal (60-80% as unchanged drug and glucuronide conjugates), biliary/fecal (20-40%)
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of elimination; biliary/fecal excretion accounts for the remainder.
Category C
Category A/B
Anticholinergic/Urinary Antispasmodic
Anticholinergic
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine."